Find policies, billing codes, payers, states, and providers
Intracoronary Drug Delivery Balloon Procedures
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This draft policy governs coverage determinations for intracoronary drug delivery balloon procedures (drug-coated/drug-eluting balloons) for Blue Cross Blue Shield - Rhode Island members across Medicare Advantage and Commercial products.
No material clinical or coverage changes in this revision.
Coverage Determinations
For Medicare Advantage plans, intracoronary drug delivery balloon procedures (drug‑coated or drug‑eluting balloons) are not covered. The policy states the evidence is insufficient to determine effects on health outcomes. For Commercial products, intracoronary drug delivery balloon procedures are considered not medically necessary for the same reason: insufficient evidence to establish benefit.
The policy rationale for Commercial product determinations is that available clinical evidence is insufficient to determine effects on health outcomes. Because the literature does not provide consistent, conclusive data demonstrating clinical benefit or durable effectiveness of intracoronary drug delivery balloon procedures compared with established alternatives, the procedure is considered not medically necessary for Commercial members.
Procedure Codes
| 0913T | Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch |
| 0914T | Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting) performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy, including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch (List separately in addition to code for percutaneous coronary stent or atherectomy intervention) |
Provider Requirements and Billing Guidance
Prior authorization — verify benefits despite 'Not applicable'
Prior authorization is listed as "Not applicable" in this policy; however, providers must still verify the member's benefits and any prior authorization requirements in the member's contract or Evidence of Coverage before performing procedures.
- Policy: "PRIOR AUTHORIZATION Not applicable"
- Confirm prior authorization requirements via the member's Evidence of Coverage / Subscriber Agreement or provider call center
Step therapy — check member contract for utilization management
This policy does not specify any step therapy requirements; providers should check the member's contract or Evidence of Coverage for any applicable utilization management rules that may apply.
- No step therapy requirements are specified in this medical policy
- Confirm any utilization management or step therapy rules in the member's Evidence of Coverage / Subscriber Agreement
Benefit verification and member-specific documentation
Confirm member-specific benefits and eligibility by referring to the member's Evidence of Coverage or Subscriber Agreement and, if needed, contact the provider call center for member-specific information before scheduling or performing the procedure.
- Refer to Evidence of Coverage / Subscriber Agreement for applicable not medically necessary/not covered benefits
- For member-specific benefits or eligibility questions, contact the provider call center as directed in the policy
Denial risk — coverage stance may lead to claim denials
Claims may be denied because Medicare Advantage plans do not cover intracoronary drug delivery balloon procedures and Commercial products consider them not medically necessary; document benefits verification and obtain any required authorizations to reduce denial risk.
- Medicare Advantage: "Intracoronary Drug Delivery Balloon Procedures are not covered"
- Commercial Products: "Intracoronary Drug Delivery Balloon Procedures are considered not medically necessary"
- Document benefit verification and member notifications to help mitigate denial and billing risk
Clinical Background
Drug‑coated balloons (DCBs) are semicompliant angioplasty balloons with an antiproliferative agent applied in a carrier matrix that transfers drug to the vessel wall during balloon inflation without leaving a permanent implant. Common agents studied include paclitaxel and agents in the sirolimus family (for example, sirolimus or everolimus). The intended mechanism is to deliver an antiproliferative drug locally to inhibit neointimal hyperplasia and reduce restenosis while avoiding placement of an additional permanent stent.
Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.